GU Cancers 2019 | Concordance of different PD-L1 assays: expression in bladder and kidney cancer

Tian Zhang

Tian Zhang, MD, of Duke Cancer Center, Durham, NC, discusses work being presented at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, on the comparability of different PD-L1 assays for both bladder and kidney cancer.

Share this video  
Similar topics
Related videos
2:33
irAEs with single-agent PD-1 vs PD-L1 inhibitors
Petros Grivas
3:48
Urothelial carcinoma: maintenance therapies
Petros Grivas
4:20
IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
Thomas Powles
3:19
PD1 & PDL1 inhibitors for mUC, where are we?
Petros Grivas
1:53
Updated FIERCE-22 data: vofatamab with pembrolizumab for mUC
Arlene Siefker-Radtke
Bladder Cancer, Genitourinary Cancer, Kidney Cancer
Checkpoint Inhibitors
GU Cancers 2019
Interview
15th February 2019
More from Tian Zhang
Characterization of circulating immune cells in metastatic urothelial cancer following treatment
Identifying predictive markers for checkpoint inhibitor response in kidney cancer
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals